Drug Topics

FEBRUARY 5, 2025

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

492

492

Pharmacy Times

FEBRUARY 5, 2025

The initiative will provide information about care models for specialists and clinical teams to improve patient outcomes in heart failure.

142

142

Drug Topics

FEBRUARY 5, 2025

ADI-001 is an investigation allogeneic gamma delta chimeric antigen receptor T cell therapy that targets CD20 for the treatment of a variety of autoimmune diseases.

FDA 329

FDA 329

Fierce Healthcare

FEBRUARY 5, 2025

Government unions and cybersecurity experts are disturbed by Elon Musk's newfound access to personal information and the country's payment infrastructure, which coordinates funds for government health programs like Medicare and Medicaid.

140

140

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

FEBRUARY 5, 2025

Researchers conducted a population-based study of women in Korea to analyze the association between age at menopause and incidence of type 2 diabetes.

247

247

Pharmacy Times

FEBRUARY 5, 2025

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board for a different approach.

117

117

PhRMA

FEBRUARY 5, 2025

One of the largest compounders in the U.S., Hims & Hers, is spending millions of dollars to run a misleading Super Bowl ad that misrepresents their unapproved GLP-1 medicines.

Compounding 100

Compounding 100

Drug Topics

FEBRUARY 5, 2025

Scott Nelson, PharmD, MS, FAMIA, ACHIP, joined Drug Topics to discuss the 2025 Pharmacy Forecast and AIs role in the future of pharmacy practice.

247

247

PharmaVoice

FEBRUARY 5, 2025

With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

100

100

Drug Topics

FEBRUARY 5, 2025

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic, discusses key benefits of incorporating biosimilars into a health system's formulary.

Mayo Clinic 190

Mayo Clinic 190

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 5, 2025

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news this week.

95

95

Drug Topics

FEBRUARY 5, 2025

Karissa Kim, PharmD, BCPS, BCACP, discusses the main challenges pharmacists face in assessing and addressing patients health literacy levels.

190

190

pharmaphorum

FEBRUARY 5, 2025

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

94

94

Drug Topics

FEBRUARY 5, 2025

Primary hyperoxaluria type 1 (PH1) is a rare genetic condition that affects the kidney, bladder, or urinary tract, and indicates high levels of oxalates in the urine.

FDA 190

FDA 190

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

FEBRUARY 5, 2025

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

89

89

Fierce Healthcare

FEBRUARY 5, 2025

Teladoc Health plans to acquire virtual preventive care provider Catapult Health as the company aims to build on its chronic condition management services and expand into at-home testing.

89

89

pharmaphorum

FEBRUARY 5, 2025

Robert F Kennedy Jr has cleared a key obstacle in his bid to become the next HHS Secretary after the Senate Finance Committee voted in his favour.

80

80

Fierce Healthcare

FEBRUARY 5, 2025

Philadelphia-based Independence Blue Cross has set a benefit exclusion for products that receive accelerated approval from the FDA in most plans. | Philadelphia-based Independence Blue Cross has set a benefit exclusion for products that receive accelerated approval from the FDA in most plans.

FDA 74

FDA 74

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

FEBRUARY 5, 2025

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to 40 billion in 2031.

Vaccines 75

Vaccines 75

Pharmacy Times

FEBRUARY 5, 2025

Gold bagging integrates health system-owned specialty pharmacies with clinical workflows to enhance safety, efficiency, outcomes, and patient experience.

Specialty Pharmacies 73

Specialty Pharmacies 73

pharmaphorum

FEBRUARY 5, 2025

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema

Labelling 68

Labelling FDA 68

Pharmacy Times

FEBRUARY 5, 2025

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

FDA 73

FDA 73

pharmaphorum

FEBRUARY 5, 2025

Liva Healthcare has acquired Momenta to create one of the largest providers of digital healthy lifestyle services to the NHS in England

64

64

Pharmacy Times

FEBRUARY 5, 2025

Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.

65

65

Pharmaceutical Technology

FEBRUARY 5, 2025

X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

Pharmacy Times

FEBRUARY 5, 2025

An inverse relationship was observed between genetic conditions associated with high levels of low-density lipoprotein cholesterol and the risk of developing T2D.

65

65

Pharmaceutical Commerce

FEBRUARY 5, 2025

The company cites a decline in sales and excess inventory as the main contributing factors.

59

59

Pharmacy Times

FEBRUARY 5, 2025

Nivolumab plus ipilimumab demonstrated a 38% reduction in the risk of disease progression or death.

65

65

Pharmaceutical Technology

FEBRUARY 5, 2025

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth.

Vaccines 59

Vaccines 59

Pharmacy Times

FEBRUARY 5, 2025

Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.

Insurance Coverage 65

Insurance Coverage Insurance FDA 65

Pharmaceutical Technology

FEBRUARY 5, 2025

Experts at the 2025 Clinical Trial Supply Europe conference will explore supply chain challenges and the impact of AI on trials.

59

59

Pharmaceutical Commerce

FEBRUARY 5, 2025

The latest news for pharma industry insiders.

59

59

Pharmaceutical Technology

FEBRUARY 5, 2025

Valnevas chikungunya vaccine Ixchiq has been greenlit by the UKs MHRA, allowing the single-dose vaccine to be made available for adults.

Vaccines 59

Vaccines 59